Search
Displaying 741–750 of 851 results for “vision connection”
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Research NewsKnown as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Foundation Fighting Blindness and Athletes for Hope Announce Strategic Partnership
Foundation NewsThis partnership will drive awareness for blinding diseases throughout the athletic community.
-
Traveling With a Guide Dog: Advice from a Seasoned Traveler
Beacon StoriesInternational Guide Dog Day, April 26th, is extra special to Janni Lehrer-Stein, as she’s celebrating the 5th anniversary of graduating with “the world’s best guide dog,” Shiloh. Janni, who has retinitis pigmentosa, has traveled to five countries outside of the United States with Shiloh and is sharing advice for traveling with a guide dog.
-
Beacon Stories
Sean was diagnosed with dry age-related macular degeneration (AMD) in his 40s. Now Sean is using his AMD as an opportunity to educate others about the spectrum of blinding diseases while fundraising for the Foundation Fighting Blindness.
-
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
In the PressOphthalmology visionary Mark S. Blumenkranz, MD, MMS, to join RD Fund’s Board.
-
Foundation Fighting Blindness to Host their Spring VisionWalks
Foundation NewsThese VisionWalk events taking place this spring will raise awareness and fund research finding treatments and cures for blinding retinal diseases.
-
Fearless Sister Duo Finding Hope
Beacon StoriesApril LuFriu and Melissa Escobio are sisters and best friends who do just about everything together, including having retinitis pigmentosa (RP).
-
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
In the PressThe investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.
.png)
